MCID: SHG001
MIFTS: 61

Shigellosis

Categories: Blood diseases, Gastrointestinal diseases, Infectious diseases, Rare diseases

Aliases & Classifications for Shigellosis

MalaCards integrated aliases for Shigellosis:

Name: Shigellosis 12 73 20 58 54 3 15 17 32
Dysentery, Bacillary 44 70
Shigella Flexneri Infectious Disease 12
Shigella Boydii Infectious Disease 12
Shigella Sonnei Infectious Disease 12
Shigella Gastroenteritis 12
Bacillary Dysentery 12
Shigella Infections 70

Characteristics:

Orphanet epidemiological data:

58
shigellosis
Inheritance: Not applicable; Prevalence: 1-9/100000 (Europe); Age of onset: All ages;

Classifications:

Orphanet: 58  
Rare infectious diseases


Summaries for Shigellosis

GARD : 20 Shigellosis is a disease caused by a group of bacteria called Shigella. Shigella is very contagious. Shigella germs are present in the stools of infected individuals for up to two weeks after symptoms have resolved. Individuals may be exposed through direct contact with an infected person or through contaminated food, water (both drinking and recreational water), or surfaces. Though anyone can get shigellosis, young children are most at risk. Symptoms of shigellosis usually begin one to two days after exposure and include diarrhea, abdominal pain, and fever. In otherwise healthy individuals, the symptoms usually resolve in 5-7 days. Those with mild shigellosis may need only rest and self-care measures to avoid dehydration (drinking fluids and electrolyte solutions). For more severe cases, antibiotics may be prescribed though some cases of shigellosis have been found to be resistant to antibiotics. Laboratory tests can be performed to determine which antibiotics are likely to be effective in an individual case. Most people make a full recovery, though it may take several months for bowel habits to return to normal. Complications are rare but may include post-infectious arthritis, bloodstream infections, seizures, or hemolytic-uremic syndrome (HUS).

MalaCards based summary : Shigellosis, also known as dysentery, bacillary, is related to dysentery and diarrhea. An important gene associated with Shigellosis is CASP1 (Caspase 1), and among its related pathways/superpathways are Shigellosis and Innate Immune System. The drugs Ciprofloxacin and Azithromycin have been mentioned in the context of this disorder. Affiliated tissues include epithelium of colon, colon and kidney, and related phenotypes are fever and bloody mucoid diarrhea

Disease Ontology : 12 A primary bacterial infectious disease that results in infection located in epithelium of colon, has material basis in Shigella boydii, has material basis in Shigella dysenteriae, has material basis in Shigella flexneri, or has material basis in Shigella sonnei, which produce toxins that can attack the lining of the large intestine, causing swelling, ulcers on the intestinal wall, and bloody diarrhea. The bacteria are transmitted by ingestion of food and water contaminated with feces.

CDC : 3 Shigellosis is an infectious disease caused by a group of bacteria called Shigella (shih-GEHL-uh). Most who are infected with Shigella develop diarrhea, fever, and stomach cramps starting a day or two after they are exposed to the bacteria. Shigellosis usually resolves in 5 to 7 days. Some people who are infected may have no symptoms at all, but may still pass the Shigella bacteria to others. The spread of Shigella can be stopped by frequent and careful handwashing with soap and taking other hygiene measures.

Wikipedia : 73 Shigellosis is an infection of the intestines caused by Shigella bacteria. Symptoms generally start one... more...

Related Diseases for Shigellosis

Diseases related to Shigellosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 424)
# Related Disease Score Top Affiliating Genes
1 dysentery 31.8 TNF IL1B CXCL8
2 diarrhea 31.3 TNF TLR4 IL1B CXCL8
3 ulcerative colitis 31.0 TNF TLR4 IL1R1 IL1B CXCL8
4 gastroenteritis 30.9 TNF IL1B CXCL8
5 paratyphoid fever 30.9 TNF IL1R1 IL1B CASP1
6 amebiasis 30.8 TNF IL1B CXCL8
7 salmonellosis 30.7 TNF TLR4 NOD1 NLRC4 IL1B IL18
8 urethritis 30.7 TNF TLR4 IL1B CXCL8
9 conjunctivitis 30.6 TNF TLR4 NLRC4 CXCL8
10 enterocolitis 30.6 TNF TLR4 NLRC4 CXCL8
11 appendicitis 30.5 TNF TLR4 IL1B CXCL8
12 toxic encephalopathy 30.5 TNF TLR4 IL1B
13 listeriosis 30.4 TNF IL1B IL18
14 exanthem 30.3 TNF IL1B IL18 CXCL8
15 proteasome-associated autoinflammatory syndrome 1 30.3 TNF TLR4 IL1R1 IL1B IL18 CXCL8
16 hepatitis a 30.3 TNF TLR4 IL1B
17 brucellosis 30.3 TNF TLR4 IL18 CXCL8
18 cysticercosis 30.2 TLR4 IL1B IL18
19 trichomoniasis 30.2 TNF IL1B CXCL8
20 bacteriuria 30.1 TLR4 IL18 CXCL8
21 typhoid fever 30.1 TNF TLR4 LTA IL1R1 IL1B CASP1
22 viral encephalitis 30.1 TNF IL1B CXCL8
23 plague 30.1 TNF TLR4 IL1B CASP1
24 toxoplasmosis 30.0 TNF TLR4 IL1B CASP1
25 helicobacter pylori infection 30.0 TNF NOD1 IL1B CXCL8
26 bronchopneumonia 30.0 TNF TLR4 IL1B CXCL8
27 perinatal necrotizing enterocolitis 30.0 TNF TLR4 LTF IL1B CXCL8
28 reactive arthritis 30.0 TNF TLR4 LTF IL1B CXCL8
29 preterm premature rupture of the membranes 30.0 TNF TLR4 IL1B CXCL8
30 q fever 30.0 TNF TLR4 IL1R1 IL1B
31 chorioamnionitis 30.0 TNF TLR4 IL1R1 IL1B IL18 CXCL8
32 irritable bowel syndrome 30.0 TNF TLR4 IL1B CXCL8
33 severe acute respiratory syndrome 30.0 TNF TLR4 IL1B CXCL8
34 toxic shock syndrome 30.0 TNF TLR4 LTA IL1R1 IL1B CXCL8
35 chagas disease 30.0 TNF TLR4 IL1B CXCL8
36 pertussis 30.0 TNF TLR4 IL1B CXCL8
37 osteomyelitis 29.9 TNF TLR4 IL1B CXCL8 CASP1
38 bacterial meningitis 29.9 TNF TLR4 IL1B IL18 CXCL8
39 peritonitis 29.9 TNF TLR4 IL1B IL18 CXCL8
40 chlamydia 29.9 TNF TLR4 NOD1 IL1B IL18 CXCL8
41 meningitis 29.8 TNF TLR4 IL1B IL18 CXCL8 CASP1
42 disease by infectious agent 29.6 TNF TLR4 LTA IL1B IL18 CAMP
43 immune deficiency disease 29.5 U2AF1 TNF LTA IL1R1 IL1B IL18
44 acute cystitis 29.4 TNF TLR4 IL1B IL18 CXCL8 CAMP
45 thrombocytopenia 29.3 U2AF1 TNF TLR4 LTA IL1B IL18
46 colitis 29.2 TNF TLR4 NOD1 LTF IL1R1 IL1B
47 malaria 28.9 TNF TLR4 LTF LTA IL1R1 IL1B
48 physiological polycythemia 10.5 TNF IL1B
49 autoinflammation with arthritis and dyskeratosis 10.4 IL18 CASP1
50 uremic pruritus 10.4 IL1B IL18

Graphical network of the top 20 diseases related to Shigellosis:



Diseases related to Shigellosis

Symptoms & Phenotypes for Shigellosis

Human phenotypes related to Shigellosis:

58 31 (show all 47)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 fever 58 31 hallmark (90%) Very frequent (99-80%) HP:0001945
2 bloody mucoid diarrhea 58 31 hallmark (90%) Very frequent (99-80%) HP:0025086
3 abdominal cramps 58 31 hallmark (90%) Very frequent (99-80%) HP:0032155
4 dehydration 58 31 frequent (33%) Frequent (79-30%) HP:0001944
5 vomiting 58 31 frequent (33%) Frequent (79-30%) HP:0002013
6 fatigue 58 31 frequent (33%) Frequent (79-30%) HP:0012378
7 anorexia 58 31 frequent (33%) Frequent (79-30%) HP:0002039
8 leukocytosis 58 31 frequent (33%) Frequent (79-30%) HP:0001974
9 nausea 58 31 frequent (33%) Frequent (79-30%) HP:0002018
10 tenesmus 58 31 frequent (33%) Frequent (79-30%) HP:0012702
11 asthenia 58 31 frequent (33%) Frequent (79-30%) HP:0025406
12 hypoglycemia 58 31 occasional (7.5%) Occasional (29-5%) HP:0001943
13 immunodeficiency 58 31 occasional (7.5%) Occasional (29-5%) HP:0002721
14 failure to thrive in infancy 58 31 occasional (7.5%) Occasional (29-5%) HP:0001531
15 hyponatremia 58 31 occasional (7.5%) Occasional (29-5%) HP:0002902
16 abscess 58 31 occasional (7.5%) Occasional (29-5%) HP:0025615
17 hypovolemic shock 58 31 occasional (7.5%) Occasional (29-5%) HP:0031274
18 ulcerative colitis 58 31 occasional (7.5%) Occasional (29-5%) HP:0100279
19 acute colitis 58 31 occasional (7.5%) Occasional (29-5%) HP:0100282
20 paralytic ileus 58 31 occasional (7.5%) Occasional (29-5%) HP:0002590
21 febrile seizure (within the age range of 3 months to 6 years) 31 occasional (7.5%) HP:0002373
22 arthritis 58 31 very rare (1%) Very rare (<4-1%) HP:0001369
23 thrombocytopenia 58 31 very rare (1%) Very rare (<4-1%) HP:0001873
24 uveitis 58 31 very rare (1%) Very rare (<4-1%) HP:0000554
25 purpura 58 31 very rare (1%) Very rare (<4-1%) HP:0000979
26 peripheral neuropathy 58 31 very rare (1%) Very rare (<4-1%) HP:0009830
27 myocarditis 58 31 very rare (1%) Very rare (<4-1%) HP:0012819
28 conjunctivitis 58 31 very rare (1%) Very rare (<4-1%) HP:0000509
29 sepsis 58 31 very rare (1%) Very rare (<4-1%) HP:0100806
30 urticaria 58 31 very rare (1%) Very rare (<4-1%) HP:0001025
31 hepatic failure 58 31 very rare (1%) Very rare (<4-1%) HP:0001399
32 cholestasis 58 31 very rare (1%) Very rare (<4-1%) HP:0001396
33 corneal ulceration 58 31 very rare (1%) Very rare (<4-1%) HP:0012804
34 pneumonia 58 31 very rare (1%) Very rare (<4-1%) HP:0002090
35 peritonitis 58 31 very rare (1%) Very rare (<4-1%) HP:0002586
36 acute kidney injury 58 31 very rare (1%) Very rare (<4-1%) HP:0001919
37 rhabdomyolysis 58 31 very rare (1%) Very rare (<4-1%) HP:0003201
38 microangiopathic hemolytic anemia 58 31 very rare (1%) Very rare (<4-1%) HP:0001937
39 intestinal perforation 58 31 very rare (1%) Very rare (<4-1%) HP:0031368
40 hemolytic-uremic syndrome 58 31 very rare (1%) Very rare (<4-1%) HP:0005575
41 bacteremia 58 31 very rare (1%) Very rare (<4-1%) HP:0031864
42 splenic abscess 58 31 very rare (1%) Very rare (<4-1%) HP:0025059
43 urethritis 58 31 very rare (1%) Very rare (<4-1%) HP:0500006
44 abdominal pain 58 Very frequent (99-80%)
45 febrile seizures 58 Occasional (29-5%)
46 abnormal blood ion concentration 58 Frequent (79-30%)
47 bloody diarrhea 58 Occasional (29-5%)

GenomeRNAi Phenotypes related to Shigellosis according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased viability with MLN4924 (a NAE inhibitor) GR00250-A-1 9.83 BAX BCL2 CASP1
2 Increased viability with MLN4924 (a NAE inhibitor) GR00250-A-2 9.83 BAX BCL2 CASP1 IL18 IL1B LTA
3 Increased viability with MLN4924 (a NAE inhibitor) GR00250-A-3 9.83 BAX BCL2
4 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.55 CXCL8 IL18 IL1B LTA NOD1 TNF
5 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.55 BAX CASP1 CXCL8 IL18 IL1B LTA
6 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-3 9.55 BAX

MGI Mouse Phenotypes related to Shigellosis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.07 BAX BCL2 CAMP CASP1 CTTN IL18
2 hematopoietic system MP:0005397 10 BAX BCL2 CAMP CASP1 CTTN IL18
3 immune system MP:0005387 9.83 BAX BCL2 CAMP CASP1 CTTN IL18
4 neoplasm MP:0002006 9.23 BAX BCL2 CASP1 IL1B IL1R1 LTF

Drugs & Therapeutics for Shigellosis

Drugs for Shigellosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 36)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ciprofloxacin Approved, Investigational Phase 4 85721-33-1 2764
2
Azithromycin Approved Phase 4 83905-01-5 447043 55185
3 Anti-Bacterial Agents Phase 4
4 Anti-Infective Agents Phase 4
5 Cytochrome P-450 Enzyme Inhibitors Phase 4
6 Fluoroquinolones Phase 4
7
Zinc Approved, Investigational Phase 3 7440-66-6 32051
8 Antibodies Phase 3
9 Immunoglobulins Phase 3
10 Trace Elements Phase 3
11 Nutrients Phase 3
12 Micronutrients Phase 3
13
Histamine Approved, Investigational Phase 2 51-45-6, 75614-87-8 774
14
Aluminum hydroxide Approved, Investigational Phase 2 21645-51-2
15
Butyric Acid Experimental, Investigational Phase 2 107-92-6 264
16 Antibiotics, Antitubercular Phase 2
17 Neurotransmitter Agents Phase 2
18
Histamine Phosphate Phase 2 51-74-1 65513
19 Histamine Antagonists Phase 2
20 Complement System Proteins Phase 1, Phase 2
21 Complement Factor H Phase 1, Phase 2
22 Immunosuppressive Agents Phase 1, Phase 2
23 Gastrointestinal Agents Phase 2
24 Adjuvants, Immunologic Phase 2
25 Antacids Phase 2
26 Anti-Ulcer Agents Phase 2
27 Vaccines Phase 2
28 Pharmaceutical Solutions Phase 2
29
Aluminum sulfate Approved Phase 1 10043-01-3
30
Formaldehyde Approved, Vet_approved 50-00-0 712
31
tannic acid Approved 1401-55-4
32
Benzocaine Approved, Investigational 1994-09-7, 94-09-7 2337
33 Ether
34 Disinfectants
35 Calcium, Dietary
36
Calcium Nutraceutical 7440-70-2 271

Interventional clinical trials:

(show all 39)
# Name Status NCT ID Phase Drugs
1 An Open Label Randomised Controlled Trial of Azithromycin Versus Ciprofloxacin for the Treatment of Children Hospitalised With Dysentery in Ho Chi Minh City, Vietnam Recruiting NCT03854929 Phase 4 Ciprofloxacin;Azithromycin
2 Phase 3 Study (Safety, Immunogenicity and Efficacy) of Improved Shigella Conjugate Vaccines in 1-4 Year Olds in Israel Completed NCT00368316 Phase 3
3 Effect of Zinc Supplementation on the Immune and Inflammatory Responses of Children to Shigella Flexneri Infection, and Correlation With Clinical Severity of Illness and Growth Following recoveryEffect of Zinc Supplementation on the Immune and Inflammatory Responses of Children to Shigella Flexneri Infection, and Correlation With Clinical Severity of Illness and Growth Following Recovery Completed NCT00321126 Phase 3 Children in the zinc group received 20 mg of elemental zinc as acetate per day in a twice-daily dose for two weeks.
4 A Comparative Double Blind Placebo-Controlled Study of Immunogenicity and Safety of Two Doses 10^5 and 10^7 CFU of SC599 Oral Vaccine, a Live Attenuated Shigella Dysenteriae 1 Vaccine Strain in Healthy Human Adult Volunteers Completed NCT00210288 Phase 2
5 Therapeutic Induction of Endogenous Antibiotics for Improved Recovery in Shigellosis Completed NCT00800930 Phase 2
6 A Phase 2a, Observer Blind, Randomized, Controlled, Single Center Study To Evaluate The Safety, Reactogenicity And Immunogenicity Of 2 Doses Of The GVGH 1790GAHB Vaccine Against Shigella Sonnei, Administered Intramuscularly In Adult Subjects From A Country Endemic For Shigellosis Completed NCT02676895 Phase 2
7 Shigella Flexneri 2a Invaplex 50 Vaccine Dose Finding and Assessment of Protection Completed NCT00485134 Phase 1, Phase 2
8 Phase 2b, Double-blind, Placebo-controlled Efficacy Challenge Study With a Candidate Bioconjugate Vaccine Against Shigella Flexneri 2a Completed NCT02646371 Phase 2
9 Efficacy, Safety and Immunogenicity of GVGH Shigella Sonnei Vaccine (1790GAHB) in a Human Challenge Study of Healthy Non-immune Adults Completed NCT03527173 Phase 2 Placebo
10 Safety, Immunogenicity, and Efficacy Studies of WRSS1, a Live Attenuated Shigella Sonnei Vaccine Candidate, in Healthy Thai Adults Completed NCT01080716 Phase 1, Phase 2
11 Safety and Immunogenicity of a Shigella-Tetravalent Bioconjugate Vaccine: A Phase 1/2 Randomized Controlled and Age Descending Study Including Dose Finding in 9 Month Old Infants Recruiting NCT04056117 Phase 1, Phase 2
12 Phase 2b Study of the Safety, Immunogenicity, and Efficacy of a Monovalent Synthetic Carbohydrate-based Conjugate Vaccine (SF2a-TT15) for Protection Against Shigella Flexneri 2a Experimental Infection Recruiting NCT04078022 Phase 2
13 A Phase 2a Age Descending Study to Investigate the Safety and Immunogenicity of the SF2a-TT15 Synthetic Carbohydrate-based Conjugate Vaccine Against Shigella Flexneri 2a in Adults, Children, and Infant Target Population in Endemic Countries. Recruiting NCT04602975 Phase 2
14 A Double-Blind Placebo Controlled Phase 2 Trial to Evaluate the Safety, Reactogenicity and Immunogenicity of a Live-Attenuated Shigella Sonnei Vaccine, WRSs2 and Determine Its Efficacy in a Challenge Model of S. Sonnei 53G in Healthy Adults Not yet recruiting NCT04242264 Phase 2
15 Safety, Immunogenicity, and Efficacy Following Experimental Challenge of CVD 1208S, a Delta guaBA, Delta Sen, Delta Set Shigella Flexneri 2a Live, Oral Vaccine: Phase IIa Vaccination Study Terminated NCT00866476 Phase 2
16 Safety, Immunogenicity, and Efficacy Following Experimental Challenge of CVD 1208S, a Delta guaBA, Delta Sen, Delta Set Shigella Flexneri 2a Live, Oral Vaccine: Phase IIb Challenge Study Terminated NCT00866242 Phase 2
17 A Phase 2a/2b, Randomized, Double-blinded, Placebo-controlled, Trial to Assess the Safety, Immunogenicity and Efficacy of Inactivated Shigella Flexneri 2a Whole Cell (Sf2aWC) Vaccine Administered With and Without Double Mutant E. Coli Heat Labile Toxin (dmLT) in Healthy Adult Subjects Withdrawn NCT03038243 Phase 2
18 Safety and Immunogenicity of Two Live, Attenuated Oral Shigella Sonnei Vaccines: WRSs2 and WRSs3 Completed NCT01336699 Phase 1
19 A Phase 1 Study to Evaluate the Safety, Tolerability, and Immunogenicity of an Oral Inactivated Whole Cell Shigella Flexneri 2a Vaccine in Healthy Adult Subjects Completed NCT01509846 Phase 1
20 Safety and Tolerability of a Candidate Bioconjugate Vaccine Against Shigella Flexneri 2a When Administered to Adult Volunteers Completed NCT02388009 Phase 1
21 A Phase 1 Randomized, Double-Blinded, Placebo-controlled, Dose-Escalation Study to Assess the Safety, Tolerability and Immunogenicity of Live Attenuated, Oral Shigella WRSS1 Vaccine in Bangladeshi Toddlers (12 to 24 Months Old) Completed NCT02934178 Phase 1
22 A Phase I Dose Escalation Study to Assess the Safety and Immunogenicity of the SF2a-TT15 Conjugate Vaccine Against S. Flexneri 2a in Healthy Adult Volunteers Completed NCT02797236 Phase 1
23 Safety and Reactogenicity of a Candidate Vaccine Against S. Dysenteriae When Administered to Healthy Adults Completed NCT01069471 Phase 1
24 A Phase 1, Randomized, Placebo Controlled, Single Center, Dose Escalation Study to Evaluate the Safety and Immunogenicity of 3 Vaccinations With Shigella Sonnei Vaccine (1790GAHB) Administered Either by Intradermal, Intranasal or Intramuscular Route in Healthy Adults. Completed NCT02034500 Phase 1
25 A Phase 1, Randomized, Observer Blinded, Placebo Controlled, Single Center, Dose Escalation Study to Evaluate the Safety and Immunogenicity of 3 Vaccinations With Shigella Sonnei Vaccine (1790GAHB) Administered Intramuscularly in Healthy Adults. Completed NCT02017899 Phase 1
26 A Phase 1 Open-label, Dose Escalating Study of Artificial Shigella Flexneri 2a InvaplexAR Administered Intranasally to Healthy, Adult Volunteers to Evaluate Safety and Immunogenicity Completed NCT02445963 Phase 1
27 A Phase 1, Open Label, Non-randomized, Single Center Study to Evaluate the Safety and Immunogenicity of 1 Booster Vaccination With (GVGH Shigella Sonnei 1790GAHB) Vaccine Administered Intramuscularly in Healthy Adults Previously Primed With Three Doses of the Same Vaccine in Study H03_01TP Compared to 1 Vaccination With (1790GAHB) Administered Intramuscularly Either to Subjects Who Received Placebo in the H03_01TP Study or naïve Subjects Who Were Not Part of H03_01TP Study Completed NCT03089879 Phase 1
28 A Single-center, Open, Phase I Clinical Trial to Evaluate Safety of S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine in Healthy Volunteers Aged Above 3 Months Completed NCT03561181 Phase 1
29 Dose-Finding Study of Lyophilized Shigella Sonnei 53G Challenge Strain Completed NCT02816346 Phase 1
30 Shigella Sonnel O-SPC/rBRU Conjugate Vaccine Completed NCT01369927 Phase 1
31 Safety, Clinical Tolerance, and Immunogenicity of CVD 1208S, a Delta guaBA, Delta Sen, Delta Set, Live, Oral Shigella Flexneri 2a Vaccine Manufactured Using cGMP Completed NCT01531530 Phase 1
32 Phase 1 Study of the Safety, Tolerability, and Immunogenicity of Oral Doses of CVD 1208S-122, a Prototype Attenuated Shigella Flexneri 2a Live Vector Expressing Enterotoxigenic Escherichia Coli Antigens Not yet recruiting NCT04634513 Phase 1
33 Shigella Sonnei OSPC-rDT Conjugate Vaccine Withdrawn NCT01399424 Phase 1 CP
34 Clinical and Microbiologic Outcomes in Patients Treated for Multidrug-resistant Shigella Infections in Dhaka, Bangladesh Unknown status NCT03778125
35 A Registry Study on Safety Surveillance of Xiyanping (a Chinese Medicine Injection) Used in China Unknown status NCT01612572
36 The Long Term Clinical Course of Postinfectious Irritable Bowel Syndrome After Shigellosis; A 10 Year Follow up Study Completed NCT02516683
37 Diagnosis of Neglected Tropical Diseases (NTDs) in Patients Presenting With Persistent Digestive Disorders (≥2 Weeks) in Côte d'Ivoire, Indonesia, Mali and Nepal Completed NCT02105714
38 Effect on Pregnancy Outcomes, Infant Growth and Development of an Egg Intervention During Pregnancy in Indonesia Recruiting NCT04694235
39 A Baseline Study in Support of Clinical Evaluation of an Oral Shigella Vaccine Development in Africa Recruiting NCT04312906

Search NIH Clinical Center for Shigellosis

Inferred drug relations via UMLS 70 / NDF-RT 51 :


BISMUTH HYDROXIDE
BISMUTH RESORCIN COMPOUND
bismuth subcarbonate
BISMUTH SUBCARBONATE PWDR
bismuth subcitrate
bismuth subgallate
BISMUTH SUBIODIDE
bismuth subnitrate
BISMUTH SUBNITRATE PWDR
bismuth subsalicylate
BISMUTH-FORMIC-IODIDE
Loperamide
Loperamide Hydrochloride

Cochrane evidence based reviews: dysentery, bacillary

Genetic Tests for Shigellosis

Anatomical Context for Shigellosis

The Foundational Model of Anatomy Ontology organs/tissues related to Shigellosis:

19
Epithelium Of Colon

MalaCards organs/tissues related to Shigellosis:

40
Colon, Kidney, Breast, Small Intestine, Bone Marrow, Bone, Spleen

Publications for Shigellosis

Articles related to Shigellosis:

(show top 50) (show all 2254)
# Title Authors PMID Year
1
New animal model of shigellosis in the Guinea pig: its usefulness for protective efficacy studies. 61 54
17277155 2007
2
Apoptosis in acute shigellosis is associated with increased production of Fas/Fas ligand, perforin, caspase-1, and caspase-3 but reduced production of Bcl-2 and interleukin-2. 54 61
12011015 2002
3
Innate immune responses in children and adults with Shigellosis. 54 61
10816520 2000
4
Induction of mRNA for tumor necrosis factor-alpha and interleukin-1 beta in mice brain, spleen and liver in an animal model of Shigella-related seizures. 54 61
10804924 2000
5
A systemic downregulation of gamma interferon production is associated with acute shigellosis. 61 54
9393836 1997
6
The interleukin 1beta-converting enzyme, caspase 1, is activated during Shigella flexneri-induced apoptosis in human monocyte-derived macrophages. 61 54
9393811 1997
7
Role of interleukin-1 in the pathogenesis of experimental shigellosis. 61 54
7635983 1995
8
Down-regulation of gamma interferon, tumor necrosis factor type I, interleukin 1 (IL-1) type I, IL-3, IL-4, and transforming growth factor beta type I receptors at the local site during the acute phase of Shigella infection. 61 54
7622234 1995
9
Measurement of fecal lactoferrin as a marker of fecal leukocytes. 61 54
1583125 1992
10
Genital Mycoplasma, Shigellosis, Zika, Pubic Lice, and Other Sexually Transmitted Infections: Neither Gone Nor Forgotten. 61
33492101 2021
11
Laboratory-based surveillance of Shigella spp. from human clinical cases in Colombia, 1997-2018 61
33761190 2021
12
Evolutionary histories and antimicrobial resistance in Shigella flexneri and Shigella sonnei in Southeast Asia. 61
33742111 2021
13
An in-vitro study on a novel six-phage cocktail against multi-drug resistant-ESBL Shigella in aquatic environment. 61
33070360 2021
14
Target Product Profile and Development Path for Shigellosis Treatment with Antibacterials. 61
33689318 2021
15
A Significant Decrease in the Incidence of Shigellosis in Israel during COVID-19 Pandemic. 61
33809746 2021
16
Host genome wide association study of infant susceptibility to Shigella-associated diarrhea. 61
33649051 2021
17
Identification and evaluation of novel vaccine candidates against Shigella flexneri through reverse vaccinology approach. 61
33452891 2021
18
[Spatio-temporal dynamics of bacillary dysentery outbreaks in Democratic Republic of the Congo, 1999-2013]. 61
33518368 2021
19
EpiMix Based Novel Vaccine Candidate for Shigella: Evidence of Prophylactic Immunity in Balb/c Mice. 61
33551691 2021
20
Genomic Drivers of Multidrug-Resistant Shigella Affecting Vulnerable Patient Populations in the United States and Abroad. 61
33500335 2021
21
Dissecting the contribution of O-Antigen and proteins to the immunogenicity of Shigella sonnei generalized modules for membrane antigens (GMMA). 61
33441861 2021
22
Shigella sonnei: virulence and antibiotic resistance. 61
32929595 2021
23
Evidence for re-infection and persistent carriage of Shigella species in adult males reporting domestically acquired infection in England. 61
32247893 2021
24
Preformulation Characterization and the Effect of Ionic Excipients on the Stability of a Novel DB Fusion Protein. 61
32916136 2021
25
Comparative genome analysis of 12 Shigella sonnei strains: virulence, resistance, and their interactions. 61
32880768 2021
26
The Prevalence of Shiga toxin-1 in non-Shigella dysenteriae isolates collected from diarrhea samples in patients, Ahvaz, Iran. 61
33292146 2020
27
Effects of El Niño/La Niña on the Number of Imported Shigellosis Cases in the Republic of Korea, 2004-2017. 61
33396622 2020
28
Public health and clinical implications of multidrug-resistant shigellosis cases in a reception centre for refugees/migrants, Greece, October-December 2019. 61
33313745 2020
29
Asymptomatic transmission shifts epidemic dynamics. 61
33525082 2020
30
Characterization of ShigETEC, a Novel Live Attenuated Combined Vaccine against Shigellae and ETEC. 61
33207794 2020
31
The Importance of Charge in Perturbing the Aromatic Glue Stabilizing the Protein-Protein Interface of Homodimeric tRNA-Guanine Transglycosylase. 61
33166460 2020
32
Prolonged Outbreak of Multidrug-Resistant Shigella sonnei Harboring blaCTX-M-27 in Victoria, Australia. 61
33020158 2020
33
A shigellosis outbreak associated with a sports festival at a kindergarten in Kitakyushu City, Japan. 61
32624341 2020
34
Factors Associated With Mortality in Toxic Encephalopathy Due to Shigellosis in Children. 61
32788427 2020
35
Differential expression of cytokine genes in THP-1-derived macrophages infected with mild and virulence strains of Shigella flexneri 2a. 61
32911076 2020
36
Intranasal Immunization of Mice with Multiepitope Chimeric Vaccine Candidate Based on Conserved Autotransporters SigA, Pic and Sap, Confers Protection against Shigella flexneri. 61
33019492 2020
37
Genome Sequences of Four Shigella boydii Strains Representative of the Major S. boydii Clades. 61
33033129 2020
38
The clinical presentation of culture-positive and culture-negative, qPCR-attributable shigellosis in the Global Enteric Multicenter Study and derivation of a Shigella severity score: implications for pediatric Shigella vaccine trials. 61
33044509 2020
39
Physical distancing and non-respiratory notifiable diseases in the Northern Territory, March-May 2020. 61
33278872 2020
40
NAIP-NLRC4-deficient mice are susceptible to shigellosis. 61
33074100 2020
41
Sex differences in shigellosis incidence rates: analysis of national data from nine countries using meta-analytic method. 61
32535632 2020
42
Characterization and structure of glyceraldehyde-3-phosphate dehydrogenase type 1 from Escherichia coli. 61
32880588 2020
43
Immune Response Characterization after Controlled Infection with Lyophilized Shigella sonnei 53G. 61
32968012 2020
44
Feasibility of containing shigellosis in Hubei Province, China: a modelling study. 61
32873241 2020
45
Lewis Blood Group Antigens are Associated with Altered Susceptibility to Shigellosis. 61
32940644 2020
46
Shigellosis Among Gay and Bisexual Men: A Qualitative Assessment to Examine Knowledge, Attitudes, and Practices. 61
32569257 2020
47
Manipulation of epithelial cell death pathways by Shigella. 61
32869315 2020
48
Pathogen-specific risk of seizure in children with moderate-to-severe diarrhoea: Case control study with follow-up. 61
32428974 2020
49
Live attenuated Salmonella Typhimurium with monophosphoryl lipid A retains ability to induce T-cell and humoral immune responses against heterologous polysaccharide of Shigella flexneri 2a. 61
32654768 2020
50
Fragment Screening Hit Draws Attention to a Novel Transient Pocket Adjacent to the Recognition Site of the tRNA-Modifying Enzyme TGT. 61
32515955 2020

Variations for Shigellosis

Expression for Shigellosis

Search GEO for disease gene expression data for Shigellosis.

Pathways for Shigellosis

Pathways related to Shigellosis according to KEGG:

36
# Name Kegg Source Accession
1 Shigellosis hsa05131

Pathways related to Shigellosis according to GeneCards Suite gene sharing:

(show top 50) (show all 74)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.01 WASL VCL UBE2D1 TNF TLR4 NOD1
2
Show member pathways
13.87 VCL TNF LTA IL1R1 IL1B IL18
3
Show member pathways
13.73 TNF TLR4 LTA IL1R1 IL1B IL18
4
Show member pathways
13.58 TNF LTA IL1R1 IL1B IL18 CXCL8
5
Show member pathways
13.48 TNF TLR4 LTA IL1R1 IL1B IL18
6
Show member pathways
13.43 VCL TNF NOD1 LTA IL1R1 IL1B
7
Show member pathways
13.33 WASL VCL TNF LTA IL1R1 IL1B
8
Show member pathways
13.27 TNF TLR4 IL1B IL18 CXCL8 CASP1
9
Show member pathways
13.01 TNF TLR4 IL1R1 IL1B CXCL8 BCL2
10
Show member pathways
12.88 TNF TLR4 IL1B IL18 CXCL8 CASP1
11 12.84 TNF LTA IL1B BCL2 BAX
12
Show member pathways
12.78 TNF LTA IL1R1 CASP1 BCL2 BAX
13
Show member pathways
12.75 TNF TLR4 LTA IL1R1 IL1B
14
Show member pathways
12.69 TNF TLR4 NOD1 NLRC4 IL1R1 IL1B
15
Show member pathways
12.68 TNF TLR4 IL1R1 IL1B IL18 BCL2
16
Show member pathways
12.67 TNF TLR4 LTA IL1R1 IL1B CASP1
17
Show member pathways
12.65 TNF IL1B IL18 BCL2 BAX
18
Show member pathways
12.47 IL1R1 IL1B BCL2 BAX
19
Show member pathways
12.42 WASL TNF TLR4 NOD1 NLRC4 IL1R1
20 12.38 TNF LTA IL1R1 BAX
21
Show member pathways
12.38 TNF TLR4 IL1R1 IL1B CXCL8
22
Show member pathways
12.37 TNF LTA IL18 CXCL8
23
Show member pathways
12.34 NOD1 IL1R1 IL1B CASP1
24
Show member pathways
12.33 TNF LTA IL1B IL18 CXCL8
25 12.33 TNF NOD1 CASP1 BCL2 BAX
26
Show member pathways
12.3 TNF TLR4 IL1B BCL2
27
Show member pathways
12.29 TNF TLR4 IL1B CASP1 BCL2 BAX
28
Show member pathways
12.27 TNF CASP1 BCL2 BAX
29
Show member pathways
12.27 TNF TLR4 IL1R1 IL1B CXCL8
30 12.26 TNF TLR4 IL1B IL18 CAMP BCL2
31 12.16 TNF IL1R1 IL1B BCL2
32 12.13 NLRC4 CASP1 BCL2 BAX
33 12.12 TNF TLR4 IL1R1 IL1B CXCL8
34 12.11 TNF TLR4 NOD1 NLRC4 IL1B IL18
35 12.1 TNF IL1B IL18 CXCL8 BCL2
36
Show member pathways
12.09 TNF CASP1 BCL2 BAX
37
Show member pathways
12.06 NOD1 NLRC4 CASP1 BCL2
38 12.06 WASL TNF TLR4 NLRC4 IL1B IL18
39 12.03 TNF IL1B CXCL8 BCL2 BAX
40 11.98 TNF TLR4 IL1B IL18 CXCL8
41 11.96 VCL TNF TLR4 IL1R1 IL1B CXCL8
42 11.95 TLR4 IL18 CXCL8 BCL2
43 11.94 WASL VCL UBE2D1 U2AF1 TNF TLR4
44 11.93 TNF TLR4 LTA IL1R1 IL1B CXCL8
45 11.91 TNF LTA IL1R1 IL1B IL18
46
Show member pathways
11.87 TNF TLR4 LTA IL1B IL18
47
Show member pathways
11.84 LTA CXCL8 BAX
48 11.8 WASL VCL CTTN
49 11.79 TNF TLR4 NOD1 IL1B CXCL8 CASP1
50 11.73 TNF TLR4 LTA

GO Terms for Shigellosis

Cellular components related to Shigellosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 specific granule lumen GO:0035580 9.33 VCL LTF CAMP
2 extracellular region GO:0005576 9.32 VCL TNF LTF LTA IL1R1 IL1B
3 IPAF inflammasome complex GO:0072557 8.96 NLRC4 CASP1

Biological processes related to Shigellosis according to GeneCards Suite gene sharing:

(show top 50) (show all 55)
# Name GO ID Score Top Affiliating Genes
1 apoptotic process GO:0006915 10.14 NOD1 NLRC4 LTA IL1B CASP1 BCL2
2 positive regulation of gene expression GO:0010628 10.11 TNF TLR4 IL1B IL18 CXCL8
3 immune response GO:0006955 10.07 TNF TLR4 LTA IL1R1 IL1B IL18
4 regulation of apoptotic process GO:0042981 10.04 NOD1 NLRC4 CASP1 BCL2 BAX
5 response to lipopolysaccharide GO:0032496 9.99 TLR4 LTA IL1B CASP1
6 defense response to bacterium GO:0042742 9.99 TNF TLR4 NOD1 NLRC4 LTF CAMP
7 defense response GO:0006952 9.98 TNF NOD1 CXCL8 CAMP
8 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 9.97 TNF TLR4 NOD1 LTF CASP1
9 activation of MAPK activity GO:0000187 9.96 TNF TLR4 NOD1 IL1B
10 defense response to Gram-positive bacterium GO:0050830 9.94 TNF NOD1 LTA CAMP
11 positive regulation of inflammatory response GO:0050729 9.92 TNF TLR4 IL1B IL18
12 regulation of inflammatory response GO:0050727 9.92 TNF TLR4 IL1R1 CASP1
13 positive regulation of interleukin-6 production GO:0032755 9.91 TNF TLR4 NOD1 IL1B
14 positive regulation of JNK cascade GO:0046330 9.91 TNF TLR4 NOD1 IL1B
15 defense response to Gram-negative bacterium GO:0050829 9.89 TLR4 LTF CAMP
16 cellular response to mechanical stimulus GO:0071260 9.89 TLR4 IL1B CASP1
17 antimicrobial humoral immune response mediated by antimicrobial peptide GO:0061844 9.88 LTF CXCL8 CAMP
18 cellular response to organic cyclic compound GO:0071407 9.88 TNF IL1B IL18
19 apoptotic signaling pathway GO:0097190 9.88 TNF TLR4 CASP1 BAX
20 activation of cysteine-type endopeptidase activity involved in apoptotic process GO:0006919 9.88 TNF NOD1 NLRC4 CASP1 BAX
21 cellular response to lipopolysaccharide GO:0071222 9.88 TNF TLR4 IL1B CXCL8 CASP1 CAMP
22 positive regulation of interleukin-8 production GO:0032757 9.87 TNF TLR4 NOD1 IL1B
23 cytokine-mediated signaling pathway GO:0019221 9.87 TNF IL1R1 IL1B IL18 CXCL8 CASP1
24 positive regulation of cysteine-type endopeptidase activity involved in apoptotic process GO:0043280 9.86 TNF NOD1 CASP1
25 intrinsic apoptotic signaling pathway in response to DNA damage GO:0008630 9.85 TNF BCL2 BAX
26 positive regulation of nitric oxide biosynthetic process GO:0045429 9.85 TNF TLR4 IL1B
27 humoral immune response GO:0006959 9.85 TNF LTF LTA BCL2
28 negative regulation of extrinsic apoptotic signaling pathway in absence of ligand GO:2001240 9.84 TNF IL1B BCL2
29 negative regulation of apoptotic signaling pathway GO:2001234 9.83 TNF BCL2 BAX
30 extrinsic apoptotic signaling pathway via death domain receptors GO:0008625 9.83 TNF BCL2 BAX
31 lipopolysaccharide-mediated signaling pathway GO:0031663 9.8 TNF TLR4 IL1B IL18
32 positive regulation of glial cell proliferation GO:0060252 9.77 TNF LTA IL1B
33 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.77 TNF TLR4 NOD1 IL1B IL18
34 cellular response to organic substance GO:0071310 9.76 IL1B CASP1 BCL2 BAX
35 inflammatory response GO:0006954 9.76 TNF TLR4 NOD1 NLRC4 IL1R1 IL1B
36 positive regulation of neuroinflammatory response GO:0150078 9.73 TNF IL1B IL18
37 detection of bacterium GO:0016045 9.72 NOD1 NLRC4
38 positive regulation of chemokine (C-X-C motif) ligand 2 production GO:2000343 9.71 TNF TLR4
39 T-helper 1 type immune response GO:0042088 9.71 TLR4 IL18
40 response to salt stress GO:0009651 9.71 TNF BAX
41 regulation of establishment of endothelial barrier GO:1903140 9.71 VCL TNF IL1B
42 interleukin-1 beta production GO:0032611 9.7 TLR4 CASP1
43 vascular endothelial growth factor production GO:0010573 9.7 TNF IL1B
44 leukocyte homeostasis GO:0001776 9.69 BCL2 BAX
45 positive regulation of humoral immune response mediated by circulating immunoglobulin GO:0002925 9.69 TNF LTA
46 positive regulation of fever generation GO:0031622 9.68 TNF IL1B
47 sequestering of triglyceride GO:0030730 9.67 TNF IL1B
48 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.66 TNF IL1B
49 positive regulation of interleukin-1 beta production GO:0032731 9.65 TNF TLR4 NOD1 NLRC4 CASP1
50 positive regulation of developmental pigmentation GO:0048087 9.64 BCL2 BAX

Molecular functions related to Shigellosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.23 WASL VCL UBE2D1 U2AF1 TNF TLR4
2 BH3 domain binding GO:0051434 9.16 BCL2 BAX
3 lipopolysaccharide binding GO:0001530 9.13 TLR4 LTF CAMP
4 cytokine activity GO:0005125 9.02 TNF LTA IL1B IL18 CXCL8

Sources for Shigellosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....